Journal ArticleDOI
Opening the lid on piano-stool complexes: An account of ruthenium(II)–arene complexes with medicinal applications
Reads0
Chats0
TLDR
The origins of the field are described, the design of compounds that inhibit enzymes are designed, the application of multinuclear systems to act as drug delivery vehicles, and the development of bioanalytical and biophysical methods are highlighted to help elucidate the mechanisms by which these compounds function.About:
This article is published in Journal of Organometallic Chemistry.The article was published on 2014-02-01. It has received 226 citations till now.read more
Citations
More filters
Journal ArticleDOI
Mechanistic Studies of Arene–Ruthenium(II) Complexes with Carbothioamidopyrazoles as Alternative Cancer Drugs
TL;DR: In this article , a series of extended bioassays to better understand their potential mechanism of antitumor activity was conducted. But the results were limited to 12 new tumor cells, analyzed by MTT, and employed a seriesof extended bio-assays, including membrane permeability, intramolecular reactive oxygen and nitrogen species (ROS/RNS) assays, mitochondrial potential changes, DNA analysis by comet assay using the electrophoresis method, measurement of cleaved PARP protein levels, and determination of apoptotic and necrotic cell fractions by fluorescence microscopy.
References
More filters
Journal ArticleDOI
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
TL;DR: In E. coli, the presence of certain group VIIIb transition metal compounds in concentrations of about 1–10 parts per million of the metal in the culture medium causes an inhibition of the cell division process, which implies that the growth process is not markedly affected.
Journal ArticleDOI
Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride
TL;DR: In this article, the same authors compared their results with available data on arene exchange in arenetricarbonylchromium complexes and discussed in terms of electronic and steric effects on metal-arene bonding.
Journal ArticleDOI
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger,Stefanie Zorbas-Seifried,Michael A. Jakupec,Bernd Kynast,Haralabos Zorbas,Bernhard K. Keppler +5 more
TL;DR: The preclinical and early clinical development of KP1019 - from bench to bedside - is recapitulated and promising activity against certain types of tumors is observed.
Journal ArticleDOI
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
Jeany M. Rademaker-Lakhai,Desiree H.J.G. van den Bongard,Dick Pluim,Jos H. Beijnen,Jan H.M. Schellens +4 more
TL;DR: The maximum-tolerated dose (MTD), profile of adverse events, and dose-limiting toxicity of NAMI-A in patients with solid tumors were determined and the ruthenium pharmacokinetic analysis revealed a linear relationship between dose and area under the concentration-time curve (AUC) of total and unbound rUThenium.
Journal ArticleDOI
Metals in Medicine
Zijian Guo,Peter J. Sadler +1 more
TL;DR: In the fight against cancer cisplatin, one of the world's best selling anticancer drugs, is being joined by other platinum, titanium, and ruthenium complexes, and metal-targeted organic agents show exciting clinical potential.